The chief executive of NHS England has issued a stark warning that the health service is “really worried” about the security of the country’s medicine supplies, citing the UK’s heavy reliance on imports and recent global instability. Jim Mackey stated that while some stocks might last for weeks, for certain products, reserves could be as low as a few days’ worth.
NHS Chief Points to Fragile Global Chains
Speaking during a radio phone-in, Mr Mackey revealed the NHS had already weathered “a couple of supply shocks in the last 12 to 18 months of key supplies.” He confirmed a specialist team was now focused on identifying risks within supply chains. His concern is underpinned by a fundamental vulnerability: the UK imports approximately 75% of the medicines it uses. This reliance on global networks, particularly for generic drugs sourced from China and India, leaves the system exposed to international disruptions, a fragility previously highlighted by the COVID-19 pandemic and changes to import processes.
The current conflict in the Middle East, involving Iran, has intensified these worries. Experts point to the Strait of Hormuz, a critical global shipping chokepoint, as a major flashpoint. While one industry source noted that most generic medicines from Asia do not transit this route, its closure could have a cascading effect. India, a global powerhouse in generic drug and active ingredient production often dubbed the “pharmacy of the world,” relies on the strait for a significant portion of its crude oil imports, which in turn impacts its manufacturing capacity and costs.
Industry Counters with Current Calm but Notes Price Alarms
Mr Mackey’s stark assessment was met with a more measured response from pharmaceutical and pharmacy bodies, who reported no direct shortages linked to the conflict at present. The Association of the British Pharmaceutical Industry, representing branded medicine makers, stated it was “not aware of any supply issues resulting from the conflict,” noting the region is not a significant medicine exporter and that supply routes are flexible.
However, frontline pharmacies are seeing early warning signs. Henry Gregg, chief executive of the National Pharmacy Association, said: “We’re not currently seeing shortages of medicine directly linked to the conflict… but pharmacies are seeing disturbing spikes in prices, which can be an early indicator of challenges.” These price surges are being driven by a complex mix of factors, including manufacturing problems, shortages of raw ingredients, and increased energy and transport costs. Disruptions to key air transit hubs in the Middle East and shipping delays are compounding logistical challenges.
To manage these price spikes and prevent suppliers from ceasing deliveries to the NHS, the Department of Health and Social Care has been forced to issue what Mr Gregg described as “unprecedented numbers of price concessions.” The mechanism hit a three-year high in February 2026.
The Critical Role of ‘Price Concessions’
This tool has become a critical, if temporary, fix for supply problems. A price concession is a temporary agreement allowing the NHS to pay more for a specific drug than the standard rate set in the official Drug Tariff. It is enacted when the DHSC identifies a market price surge that threatens supply. By conceding a higher price, the department aims to circumvent the immediate shortage, ensuring that manufacturers and wholesalers continue to supply the UK market and that stocks keep arriving at pharmacies. The practice underscores the vulnerability created by the NHS’s historically low drug prices in a competitive global market.
The UK is already grappling with significant shortages unrelated to the current geopolitical tension. There is a nationwide shortage of aspirin and the strong painkiller co-codamol. Furthermore, supplies of hormone replacement therapy (HRT) and drugs to treat ADHD and epilepsy have been unreliable for years, leading in some cases to the implementation of “Serious Shortage Protocols” which allow pharmacists to dispense alternatives without a new prescription.
Government Stresses Monitoring and Resilience Plans
In response to the concerns, a government spokesperson sought to provide reassurance, stating: “There are currently no reported medicine shortages as a result of conflict in the Middle East. We continue to monitor the situation closely for any impacts on the medical supply chain.” The spokesperson added that the DHSC has established processes to manage disruption and actively monitors emerging threats.
Longer-term efforts to bolster resilience are outlined in official policy, including the government’s 10 Year Health Plan for England, which includes measures to improve the management of medicines shortages. There is also a commitment to consult on allowing community pharmacists greater flexibility to supply alternative formulations without a new prescription. The pharmaceutical industry has emphasized the need for a policy environment that encourages investment in UK manufacturing facilities and strengthens international partnerships to secure supply.